Board of Directors

Chairman of the Board since 2023

Julian has more than 25 years of experience in finance and international business development within the pharmaceutical and technology industries including Oasmia Pharmaceutical AB. Julian is an entrepreneur who ran his own companies for many years in several different business areas, primarily pharmaceutical development. Is an active investor and through companies also a major owner in a number of listed companies.

Number of shares: –

Education: Economist

Other assignments: Board member of Maida Vale Capital AB and Hunterhex AB.

Independent in relation to the company and its management but not to major shareholders. 

Board member since 2021

Anders has more than 25 years of experience within international finance and business development in the pharmaceutical– and medical device industries. His experience includes Business- and Corporate Development from Pharmacia & Upjohn, Q-Med AB (publ), partner and CEO at venture  capital firm Nexttobe AB and Executive VP and CFO at Oasmia Pharmaceutical AB (publ). In addition, Anders has extensive board experience from pharma- and tech sectors including, but not limited to, Hansa Biopharma AB (publ), Biolamina AB, Delta Projects AB,  Selego AB. 

Number of shares *): 14,632,418 shares through Maida Vale Capital AB 

Education: BSc in Business Administration and Economics at Uppsala University  

Ongoing assignments: Chairman of the board of Maida Vale Capital AB, Terranet AB, Rosland Nordic AB, Black T Quant AB and board member of Hunterhex International Inc, Hunterhex AB,  Evolutience Pharmaceutical AB,  Wonderboo AB, Emotra AB and Challengehop Inc.   

Independent in relation to the company and its management but not to major shareholders. 

Board member since 2020

Per-Göran has 35 years of experience from the pharmaceutical industry. He has extensive experience in pharmacology and neuropharmacology from Kabi, Kabi Pharmacia, Pharmacia & Upjohn and Pharmacia, AstraZeneca and Albireo. Per-Göran is the founder of Albireo AB and was VP Development for Albireo Pharma Inc and its subsidiary Albireo AB and is affiliated with the Division of Translational Alzheimer Neurobiology, Karolinska Institute, Stockholm.

Number of shares *): 65,210 shares and 111,111 shares through company

Education: MSc in Chemistry, PhD in Medical Science, Adjunct Professor of Neuroscience at Uppsala University

Ongoing assignments: Board member of Dicot AB, Co-opted to the Center for Alzheimer Research at Karolinska Institute

Independent in relation to both the company and its management as well as to major shareholders.

Board member since 2015

Clas is a physician at the Neurology clinic and at the laboratory for clinical immunology at Sahlgrenska University Hospital in Gothenburg. Since 2001 he has conducted research within Multiple Sclerosis (MS) at the hospital’s Multiple sclerosis centre and the Department of Clinical Neuroscience, University of Gothenburg. In addition to academic research, he has participated in several clinical drug trials in MS led by Biogen-Idec, Merck, Novartis, Roche and Sanofi, several of which resulted in today’s standard treatments for MS.

Number of shares *): 20,000 shares

Education: MD and PhD in Medicine, Senior consultant in Neurology and Clinical Immunology

Other assignments: –

Independent in relation to both the company and its management as well as to major shareholders.

Board member since 2018

Carol is an R&D and pharmaceutical development expert with more than 30 years of experience in UK and US-based pharmaceutical and biotechnology companies focusing on drug acquisition and profiling of NCE biology. She has played a key role in GSK Biopharmaceuticals, including management in pharmaceutical research and development activities in several therapeutic areas, especially in the areas of immuno-inflammatory diseases and neuroscience with an emphasis on translational medicine. She recently managed a semi-philanthropic dementia fund with a central focus on identifying and developing new disease-modified mechanisms for the treatment of all different types of dementia. She has over 90 articles published in scientific journals. Until recently Carol was the Director of Research and Managing Director of EDoN, a global early detection initiative at Alzheimer’s Research UK. She worked as Chief Medical and Scientific Officer at Small Pharma and is currently an independent biomedical consultant.

Number of shares: –

Education: BSc, PhD in Neuro Pharmacology

Ongoing assignments: –

Independent in relation to both the company and its management as well as to major shareholders.

Board member since 2018

Anders has held several senior roles in Astra, AstraZeneca, CV Therapeutics, Actogenics and Tikomed AB. He has previous experience in management, business development, financing and pharmaceutical development.

Number of shares: –

Education: Trained dentist (DDS)

Ongoing assignments: Chairman of the of Sobrera Pharma AB and SiMSen Diagnostics AB. Board member of Nexo Therapeutics, Transmed Gothenburg AB, Xandrax AB, CerInvent AB, Nexo Therapeutics AB and Anders Waas AB.

Independent in relation to both the company and its management and dependent of major shareholders.